Mylan emerged as the world’s biggest generic pharmaceutical company in 2018 despite a decline in net sales, as the industry peers face turbulence due to price erosion and pricing regulations. Pharmaceutical-technology.com lists the world’s biggest generic drug sellers based on revenues from January to December 2018. Except Teva Pharmaceuticals and Sanofi, none others from the top ten list currently market patented drugs.
Top ten generic pharmaceutical companies in 2018: Ranking the top ten biggest companies
10. Sanofi
9. Dr. Reddy’s
8. Sawai Pharmaceutical
7. Hikma Pharmaceuticals
6. Cipla
5. Lupin
4. Sun Pharmaceutical Industries
3. Teva Pharmaceutical
2. Sandoz
1. Mylan
Mylan – $11.26bn
Mylan recorded a 4% drop in total net sales in 2018 compared to 2017. The decline in revenue was attributed to the lower uptake of generic Copaxone, which is indicated for multiple sclerosis, and delay in the approval of Advair, a generic drug for asthma.
The company earned net revenues of $4.09bn in North America and $4.15bn in Europe. France was the biggest European market for the company’s generic prescription drugs, followed by Italy. The ROW segment witnessed $3.01bn in revenues in 2018. Japan emerged as the fastest growing generics market in the segment, while Australia was the biggest market in terms of volume.
The company launched more than ten complex generics and biosimilar products in 2018 such as Bivalirudin (generic Angiomax®), Tadalafil (generic Adcirca®), Dalfampridine (generic Ampyra®), and Mesalamine Rectal Suppository (generic of Allergan’s Canasa® Rectal Suppository).
Mylan is a US-based pharmaceutical company with a global portfolio of more than 7,500 products, including generic, branded generic, branded pharmaceutical, and OTC drugs.
